Samsung Biologics Commercializes Self-Developed Cell Line... "Will Increase New Drug Success Rate"

[Asia Economy Reporter Cho Hyun-ui] Samsung Biologics officially announced its self-developed cell line ‘S-Choice’ on the 5th. A cell line is a cell that proliferates massively outside the body to produce desired antibody drugs.

S-Choice is characterized by rapid proliferation and long-term survival compared to other cell lines. The cell expression amount is over 7 grams per liter titer (quantified antibody amount in the culture medium) immediately after cell line development, which is about twice the industry average (approximately 3-4 grams per liter at the time of commercial production).

The cell survival rate is over 90% until 21 days of serum culture, which is higher than the industry average (14 days). A Samsung Biologics official explained, "The higher the cell survival rate, the better we can select high-quality cell lines for mass production, which in turn increases productivity."

Another strength is the cell division speed of 18-20 hours, faster than major competitors’ cell lines (a full day, 24 hours). When culturing S-Choice with ‘Beacon,’ the latest cell incubator recently introduced by Samsung Biologics, the time required for cell line development is shortened from the industry average of 4 months to 3 months.

Kim Tae-han, CEO of Samsung Biologics, said, “Through S-Choice, we can provide services with overwhelming speed and quality compared to the existing global biopharmaceutical industry,” adding, “We expect that the powerful performance of S-Choice will enhance customer satisfaction, meet global pharmaceutical supply demands, and contribute to increasing the success rate of new drug development.”

This content was produced with the assistance of AI translation services.